Showing 5141-5150 of 5621 results for "".
- The American Academy of Optometry Foundation Selects the 2019 Bert C. and Lydia M. Corwin Contact Lens Residency Award Recipienthttps://modernod.com/news/the-american-academy-of-optometry-foundation-selects-the-2019-bert-c-and-lydia-m-corwin-contact-lens-residency-award-recipient/2476831/The American Academy of Optometry has named Jocelyn Ou, OD, this year’s recipient of the Bert C. and Lydia M. Corwin Contact Lens Residency award. Dr. Ou is a cornea and contact lens resident at the Ketchum Health University Eye Center in Anaheim, California, and was ch
- Staar Surgical Announces FDA IDE Clinical Study Approvalhttps://modernod.com/news/staar-surgical-announces-fda-ide-clinical-study-approval/2476825/Staar Surgical announced that the FDA, in a letter dated August 23, 2019, stated that it has determined that Staar has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ Visian Implantable Collamer Lens for myopia, and EVO/EVO+ Visian Tor
- Alcon Introduces AcrySof IQ PanOptix Trifocal IOL in the US, the First and Only FDA-Approved Trifocal Lenshttps://modernod.com/news/alcon-introduces-acrysof-iq-panoptix-trifocal-iol-in-the-us-the-first-and-only-fda-approved-trifocal-lens/2476827/Alcon announced the FDA approval and the initial commercial launch of the AcrySof IQ PanOptix Trifocal IOL, the first and only trifocal lens approved in the United States. PanOptix is clinically shown to deliver an exceptional combination of near, intermediate, and distance vision while reducing
- ProtoKinetix: Tests Show AAGP-Preserved and Enabled Retinal Cells to Mature Without Compromise after 5-Month Milestonehttps://modernod.com/news/protokinetix-tests-show-aagp-preserved-and-enabled-retinal-cells-to-mature-without-compromise-after-5-month-milestone/2476822/ProtoKinetix updated shareholders regarding ongoing third stage testing of retinal cell replacement therapy at the University of British Columbia. As previously reported, the company demonstrated the ability of AAGP to protect transplanted cells in a preclinical experimental model of retinal dege
- Quantel Medical Announces Acquisition of Optotek Medicalhttps://modernod.com/news/quantel-medical-announces-acquisition-of-optotek-medical/2476821/Quantel Medical announced that it is acquiring ophthalmic medical device maker Optotek Medical. This acquisition comes after a long collaboration between the two companies through the development and supply of devices
- Iconic Therapeutics Signs Ophthalmology Option Agreement With Novartishttps://modernod.com/news/iconic-therapeutics-signs-ophthalmology-option-agreement-with-novartis/2476818/Iconic Therapeutics announced that the company has signed an agreement with Novartis in which Novartis will have an option on Iconic’s ophthalmology program, now in preclinical development. Novartis made an upfront payment and an equity investment in Iconic. The details of investment were not dis
- High Levels of Exhaust Pollutants May Raise Risk for AMDhttps://modernod.com/news/high-levels-of-exhaust-pollutants-may-raise-risk-for-amd/2476819/Exposure to high levels of exhaust may raise the risk of age-related macular degeneration (AMD), a new study suggests, according to a Reuters report. In a study of nearly 40,000 people in Taiwan, researchers found that high levels o
- Trump Administration to Appeal Ruling Barring Proposed Drug Price Disclosure Policyhttps://modernod.com/news/trump-administration-to-appeal-ruling-barring-proposed-drug-price-disclosure-policy/2476816/The administration of US President Donald Trump plans to appeal a recent federal court decision striking down a Department of
- Nidek Launches the Mirante Scanning Laser Ophthalmoscopehttps://modernod.com/news/nidek-launches-the-mirante-scanning-laser-ophthalmoscope/2479546/Nidek has announced the launch of the Mirante Scanning Laser Ophthalmoscope. The Mirante is a multimodal fundus imaging platform that combines high definition SLO and OCT with ultra widefield imaging. The multimodal p
- Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Wet AMD and DMEhttps://modernod.com/news/aerie-pharmaceuticals-initiates-first-in-human-clinical-trial-of-ar-13503-sustained-release-intravitreal-implant-in-patients-with-wet-amd-and-dme/2476812/Aerie Pharmaceuticals announced the commencement of patient dosing in a first-in-human clinical trial of AR-13503 Sustained Release (SR) implant in patients with neovascular age-related macular degeneration (AMD) or diabetic macular edema (DME). This multi-arm, 24-week study (AR-13503-CS20